Abstracts tagged "T Cell"

Abstract Number: 0991 • ACR Convergence 2025
MTHFD2 is a Novel Metabolic Target in Autoimmune Disease
Laura McMillan, Celia Evans, Marina Makrecka-Kuka, Niamh Richmond, Gareth Davies, Hamel Patel, Michael Herdman, Mark Whitmarsh, Alessandro Mazzacani, Peter Bunyard, Madduri Ravin Rao and Iain Kilty, Sitryx Therapeutics, Oxford, United Kingdom
Background/Purpose: Aberrant activation and persistence of adaptive immune responses play a central role in autoimmune pathogenesis. Where traditional immunosuppressive therapies offer a broad targeting approach,…
Abstract Number: 0887 • ACR Convergence 2025
Dynamics of cytotoxic and regulatory CD8 T cells underlies outcome in ICI-myotoxicity
Runci Wang¹, Chunyan Xiang², Adrien Procureur³, Julian Sanchez-Dal Cin³, Qing Wang⁴, Xinyue Lian⁵, Michelle Rosenzwajg³, Yves Allenbach⁶, Deepak Rao⁷, Qiong Fu⁸, Nan Shen⁹, Joe-Elie Salem³ and Shuang Ye¹⁰, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ²Shanghai Institute of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), shanghai, China (People's Republic), ³Sorbonne Université, Paris, France, ⁴Zhongshan Hospital, Shanghai, China (People's Republic), ⁵Renji Hospital, Shanghai, China (People's Republic), ⁶SORBONNE UNIVERSITE, Paris, France, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Renji Hospital, Shanghai, Shanghai, China, ⁹Shanghai Jiang Tong University School of Medicine, Shanghai, China (People's Republic), ¹⁰Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Immune checkpoint inhibitor (ICI) therapies for cancer can induce immune-related adverse events (irAEs) involving musculoskeletal (MSK) systems. ICI myotoxicity (ICI-M) can present as a…
Abstract Number: 0015 • ACR Convergence 2025
CDR111 is a novel CD19 and BCMA dual-targeting T cell engager (TCE) for the treatment of severe and refractory autoimmune diseases
Philipp Richle, Stephanie Jungmichel, Alessio Vantellini, André Fonseca, Anna Howald, Fabian Scheifele, Loredana iuliano, Ariadna Vilarrasa, Romina Doerig, Hannes Merten, Philip Knobel, Daniel Lenherr-Frey, Christian Leisner and Leonardo Borras, CDR-Life, Horgen, Zurich, Switzerland
Background/Purpose: B cells and plasma cells are central to the pathogenesis of many autoimmune diseases. While B cell depletion therapies (BCDTs), such as anti-CD20 monoclonal…
Abstract Number: 1653 • ACR Convergence 2025
Gut-joint lymphocyte trafficking functions to regulate systemic immunity
Sarah Danielson¹, Sucai Liu² and Kristine Kuhn³, ¹University of Colorado Anschutz Medical Campus, Aurora, ²University of Colorado School of Medicine, Aurora, CO, ³²⁰²² - ²⁰²³ / Adult/ University of Colorado, Aurora, CO
Background/Purpose: The gut-joint and mucosal origins hypotheses postulate that immune alterations in mucosal sites may precede and impact the development of rheumatoid arthritis and spondyloarthritis.…
Abstract Number: 0990 • ACR Convergence 2025
An Fc-engineered Agonistic Anti-PD-1 Antibody Selectively Depletes PD-1+ cells and Attenuates T cell activation in vitro and in vivo in a Xenogeneic Graft-versus-Host Disease (GvHD) model
laetitia Pouzol, Patrizia Murer, Nicole Egli, Laetitia Petersen, Anais Zurbach, christian Stocker, alexander Rau, andreas Katopodis and christoph huber, Anaveon, Basel, Switzerland
Background/Purpose: PD-1+ T cells play a pivotal role in the pathogenesis of autoimmune diseases, including rheumatoid arthritis. Therapeutic antibodies targeting PD-1 with both depleting and…
Abstract Number: 0886 • ACR Convergence 2025
A First-in-Class Biologic Selectively Targeting HLA-B27-Reactive T Cells in Ankylosing Spondylitis
Patrick Holec, Megan Reitars, Nishant Singh and Isabelle Larsen, Fletcher Biosciences, Cambridge, MA
Background/Purpose: Ankylosing spondylitis (AS), a chronic autoimmune disease strongly associated with HLA-B27:05, is currently managed with therapies that broadly suppress inflammation instead of targeting disease-driving…
Abstract Number: 0009 • ACR Convergence 2025
MRT-6160, a VAV1-Directed Molecular Glue Degrader, Attenuates T and B Cell Effector Functions and Inhibits Disease Progression in a Spontaneous MRL-Faslpr Mouse Model
Adam Cartwright¹, Lucas Gyger¹, Foram Desai², Shailee Vora², Anna Kostikova¹, Xudong Wang², Peter Trenh², Katie May², Sophia Nguyen², Chris King², Daniel Lam², Xavi Lucas¹, Mary Zlotosch², Elisa Liardo¹, Daric Wible², Ilaria Lamberto², Bradley Demarco², Debora Bonenfant¹, Sharon Townson², Eswar Krishnan², Filip Janku², John Castle¹, Laura McAllister¹, Alison Paterson² and Marisa Peluso², ¹Monte Rosa Therapeutics, Basel, Switzerland, ²Monte Rosa Therapeutics, Boston, MA
Background/Purpose: VAV1, an immune cell restricted guanine nucleotide exchange factor (GEF) and scaffolding protein, plays a critical role in mediating T- and B-cell receptor activity.…
Abstract Number: L03 • ACR Convergence 2024
CD9 Expressing T Follicular Helper Cells Are a Highly Functional Subset Expanded in Systemic Lupus Erythematosus
Kyleigh Brimmer¹, Olivia Antao¹, Daniel Mayer¹, Gina Sanchez¹, Rebecca Francis¹, Htay Htay Kyi², Mary Salim², Boyan Xia², Eugenio Capitle² and Jason Weinstein¹, ¹Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, NJ, ²Division of Allergy, Immunology and Rheumatology, University Hospital, Newark, NJ
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by the generation of autoantibodies that promote tissue injury. The development of pathogenic autoantibody-secreting B cells in lupus…
Abstract Number: L16 • ACR Convergence 2024
Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial
Megan Clowse¹, David Isenberg², Joan Merrill³, Thomas Dörner⁴, Michelle Petri⁵, Edward Vital⁶, Eric Morand⁷, Teri Jimenez⁸, Stephen Brookes⁹, Janine Gaiha-Rohrbach¹⁰, Christophe Martin¹¹, Annette Nelde¹² and Christian Stach¹³, ¹Division of Rheumatology and Immunology, Duke University, Durham, NC, ²Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine, University College London, London, United Kingdom, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine/Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ⁸UCB, Raleigh, NC, ⁹Biogen, Maidenhead, United Kingdom, ¹⁰Biogen, Cambridge, MA, ¹¹UCB, Slough, United Kingdom, ¹²Biogen, Baar, Switzerland, ¹³UCB, Monheim am Rhein, Germany
Background/Purpose: Dapirolizumab pegol (DZP) is a novel, polyethylene glycol (PEG)-conjugated antigen-binding (Fab') fragment, lacking an Fc domain, that inhibits CD40L signaling. By binding to CD40L,…
Abstract Number: 0246 • ACR Convergence 2024
Selectively Targeting TRBV11-2+ T Cells in Multisystem Inflammatory Syndrome in Children (MIS-C) Using Bispecific T Cell-Engaging Antibodies
Elana Shaw, Stephanie Glavaris, Brian Mog, Alexander Pearlman, Sarah DiNapoli, Jin Liu, Kyle J. Kaeo, Kenneth W. Kinzler, Chetan Bettegowda, Shibin Zhou, Bert Vogelstein, Suman Paul and Maximilian F. Konig, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare but potentially deadly immune complication after infection with SARS-CoV-2. In patients with MIS-C, a striking…
Abstract Number: 0943 • ACR Convergence 2024
Cytosporone B, a Selective Agonist of Nr4a1, Inhibits Th17 Differentiation and Alleviates Experimental Arthritis in SKG Mice
Yoichi Nakayama¹, Ryosuke Hiwa², Ayaka Okubo¹, Mikihito Shoji³, Mirei Shirakashi⁴, Hideaki Tsuji², Koji Kitagori⁵, Ran Nakashima², Shuji Akizuki⁶, Hajime Yoshifuji² and Akio Morinobu⁷, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan, ²Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³[email protected], Kyoto, Kyoto, Japan, ⁴Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, ⁵Occupational Welfare Division, Agency for Health, Safety and Environment, Kyoto University,, Kyoto, Kyoto, Japan, ⁶Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto City, Japan, ⁷Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan
Background/Purpose: NR4A family regulates T cell tolerance mechanisms, including thymic-negative selection, Treg generation and function, and anergy/exhaustion. Among the three NR4A nuclear receptors, Nur77, the…
Abstract Number: 1772 • ACR Convergence 2024
Modeling and Predicting HLH Through Measurement of Immune Synapse Duration, Cytokine Production, and Target Cell Death
Anastasia Frank-Kamenetskii¹, Jemy Varghese², Jeremy Morrissette³, Hannah Klinghoffer⁴, Caroline Diorio⁵, Janis Burkhardt⁶ and Scott Canna², ¹CHOP/UPENN, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³University of Pennsylvania - Perelman School of Medicine, Philadelphia, PA, ⁴The Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Division of Pediatric Oncology, The Children’s Hospital of Philadelphia, Philadelphia, PA, ⁶The Children's Hospital of Philadelphia, Philadelphia
Background/Purpose: Hyperinflammation is a life-threatening systemic inflammatory state most commonly associated with Hemophagocytic Lymphohistiocytosis (HLH) and Macrophage Activation Syndrome (MAS), but observed in nearly all inflammatory…
Abstract Number: 1846 • ACR Convergence 2024
Citrullinated Vimentin-reactive Immune-regulatory CD4+CD39+TIGIThi T Cells Expand During Drug Free Remission in HLA-DR Shared-epitope+ ACPA+ Rheumatoid Arthritis
Amy Anderson¹, Henrique de Paula Lemos¹, Hendrik Nel², Sofia Sorbet Santiago¹, Fiona Rayner³, Abbie Degnan¹, Imogen Wilson¹, Julie Diboll¹, Jasmine Sim¹, Andrew Melville⁴, Stefan Siebert⁴, Iain McInnes⁵, Carl Goodyear⁴, Catharien Hilkens¹, Andrew Filer⁶, Karim Raza⁶, Christopher Buckley⁷, Hugh Reid⁸, Kenneth Baker¹, Arthur Pratt³, Jamie Rossjohn⁸, Ranjeny Thomas⁹ and John Isaacs¹, ¹Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Frazer Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia, ³Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ⁴School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁵University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁶Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, ⁷Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ⁸Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria, Australia, ⁹University of Queensland, Brisbane, Australia
Background/Purpose: There is a need for immunotherapy that sustains symptom remission without ongoing need for disease modifying drugs (DMARDs). In a phase 1b trial of…
Abstract Number: 1866 • ACR Convergence 2024
Identification of Sjögren’s Disease-Associated CD4+ T Cell Receptor (TCR) Motifs and Repertoire Landscape Through TCR Deep Sequencing
Ananth Aditya Jupudi¹, Michelle L. Joachims², Christina Lawrence², Charmaine Lopez-Davis², Bhuwan Khatri², Astrid Rasmussen², Kiely Grundahl², Robert Hal Scofield², Judith James², Joel Guthridge², Christopher Lessard², Linda F. Thompson² and A. Darise Farris², ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Sjögren’s disease (SjD) is a chronic rheumatic autoimmune disorder characterized by focal lymphocytic infiltration of the lacrimal and salivary glands (SG). CD4+ T cells…
Abstract Number: 2677 • ACR Convergence 2024
N-Acetylcysteine Blocks the Mechanistic Target of Rapamycin in Pro-Inflammatory Effector-Memory CD4 and CD8 T Cells Re-Expressing CD45RA in Patients with Active Systemic Lupus Erythematosus
Joy Park¹, Lanlan Ji¹, Jorge Cabezas¹, Xiaojing Wang², Bryan Blaker¹, Dilip Rao¹, Aparna Godavarthy¹, Lucero Blaker¹, FNU Ruchi¹, Ioana Coman¹, Nancy Olsen³, Joshua Lewis², Mariko Ishimori⁴, Kyriakos Kirou⁵, Christina Donath¹, Sara Kahlown⁶, Damira Sereda¹, Marlene Marte Furment¹, Sandy Nasr⁷, Sravani Lokineni¹, rosalind Ramsey-Goldman⁸, Michael Weisman⁹, Arthur Weinstein¹⁰, Cynthia Aranow¹¹, Banki Katalin¹², Michael McDermott¹³, Daniel Wallace¹⁴ and Andras Perl¹, ¹SUNY, Syracuse, NY, ²SUNY Upstate Medical University, Syracuse, NY, ³Penn State University/Milton S Hershey, Hershey, PA, ⁴Cedars-Sinai Health System, Los Angeles, CA, ⁵Hospital for Special Surgery, New York, NY, ⁶SUNY Upstate University Hospital, Department of Medicine, Rheumatology Fellowship Program, Syracuse, NY, ⁷SUNY Upstate University Hospital, syracuse, NY, ⁸Northwestern University, Chicago, IL, ⁹Stanford University, Los Angeles, CA, ¹⁰Georgetown University, Pasadena, CA, ¹¹Feinstein Institutes for Medical Research, New York, NY, ¹²SUNY Upstate University Hospital, Department of Pathology, Syracuse, NY, ¹³University of Rochester, Rochester, NY, ¹⁴Cedars Sinai, Los Angeles, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology with significant mortality attributed to infections due to toxicity of immunosuppressant medications. Our…

« Previous Page
1
…
3
4
5
6
7
…
26
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].